You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.
Exclusive: Senators ask Medicare for a pay bump for drugs used with PET scans
Sen. Marsha Blackburn (R-Tenn.) is leading a bipartisan group of senators to ask Medicare officials to bump payment for drugs paired with diagnostic scans that are used for, among other things, assessing patients’ eligibility for a new class of Alzheimer’s drugs, my co-author Rachel Cohrs Zhang reports.
Medicare last year relaxed restrictions that limited Medicare patients to one PET scan in their lifetimes, and only in the context of a clinical trial. Now, the group of 15 senators including Sens. Tammy Baldwin (D-Wis.), Susan Collins (R-Maine), Shelley Moore Capito (R-W.V.), Joe Manchin (D-W.V.) and Maggie Hasssan (D-N.H.), is asking Medicare to pay for the drugs used with the scans separately, instead of having them bundled in with other services.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect